Cargando…
The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial
BACKGROUND: Herpes zoster and its related complications are associated with significant medical burden, which negatively affects quality of life and daily functioning of the patients. The recently licensed recombinant zoster vaccine (RZV) offers high efficacy but is associated with local and systemi...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625580/ https://www.ncbi.nlm.nih.gov/pubmed/30256905 http://dx.doi.org/10.1093/gerona/gly218 |
_version_ | 1783434444065996800 |
---|---|
author | Schmader, Kenneth E Levin, Myron J Grupping, Katrijn Matthews, Sean Butuk, David Chen, Michael Idrissi, Mohamed El Fissette, Laurence A Fogarty, Charles Hartley, Paul Klein, Nicola P Nevarez, Max Uusinarkaus, Kari Oostvogels, Lidia Curran, Desmond |
author_facet | Schmader, Kenneth E Levin, Myron J Grupping, Katrijn Matthews, Sean Butuk, David Chen, Michael Idrissi, Mohamed El Fissette, Laurence A Fogarty, Charles Hartley, Paul Klein, Nicola P Nevarez, Max Uusinarkaus, Kari Oostvogels, Lidia Curran, Desmond |
author_sort | Schmader, Kenneth E |
collection | PubMed |
description | BACKGROUND: Herpes zoster and its related complications are associated with significant medical burden, which negatively affects quality of life and daily functioning of the patients. The recently licensed recombinant zoster vaccine (RZV) offers high efficacy but is associated with local and systemic reactions. This study assessed the impact of RZV on the quality of life and daily functioning of participants and implications for caregivers. METHODS: Four hundred and one adults aged 50 years or older received single RZV doses at 0 and 2 months in this open-label, single-arm, multicenter study (NCT02979639). Change in mean SF-36 Physical Functioning score following first-dose administration, quality of life, reactogenicity, safety, productivity loss, and health care resource utilization was assessed. The current analysis was performed post-vaccine dose-1; safety follow-up will continue until 1 year post-dose-2. RESULTS: The most common solicited local symptoms were injection-site pain (77.5%), redness (23.0%), and swelling (13.3%); the most frequent solicited systemic reactions were fatigue (33.5%), headache (28.3%), and myalgia (26.8%). Grade 3 reactogenicity occurred in 9.5% of participants and was associated with a transient clinically important decrease in SF-36 Physical Functioning score (affecting activities such as walking, carrying groceries, climbing stairs) on Days 1 and 2 post-first vaccination. No clinically meaningful reductions in mean SF-36 Physical Functioning scale scores from pre- to post-RZV dose-1 were observed (mean +1.9 points, primary end point), and no overall quality-adjusted-life-year loss was recorded post-dose-1. Five participants reported lost workdays; caregiver workload was not increased. CONCLUSIONS: Overall, the physical functioning and quality of life of older adults were not affected by a first RZV dose. The observed reactogenicity was consistent with previous studies. |
format | Online Article Text |
id | pubmed-6625580 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-66255802019-07-17 The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial Schmader, Kenneth E Levin, Myron J Grupping, Katrijn Matthews, Sean Butuk, David Chen, Michael Idrissi, Mohamed El Fissette, Laurence A Fogarty, Charles Hartley, Paul Klein, Nicola P Nevarez, Max Uusinarkaus, Kari Oostvogels, Lidia Curran, Desmond J Gerontol A Biol Sci Med Sci The Journal of Gerontology: Translational Section BACKGROUND: Herpes zoster and its related complications are associated with significant medical burden, which negatively affects quality of life and daily functioning of the patients. The recently licensed recombinant zoster vaccine (RZV) offers high efficacy but is associated with local and systemic reactions. This study assessed the impact of RZV on the quality of life and daily functioning of participants and implications for caregivers. METHODS: Four hundred and one adults aged 50 years or older received single RZV doses at 0 and 2 months in this open-label, single-arm, multicenter study (NCT02979639). Change in mean SF-36 Physical Functioning score following first-dose administration, quality of life, reactogenicity, safety, productivity loss, and health care resource utilization was assessed. The current analysis was performed post-vaccine dose-1; safety follow-up will continue until 1 year post-dose-2. RESULTS: The most common solicited local symptoms were injection-site pain (77.5%), redness (23.0%), and swelling (13.3%); the most frequent solicited systemic reactions were fatigue (33.5%), headache (28.3%), and myalgia (26.8%). Grade 3 reactogenicity occurred in 9.5% of participants and was associated with a transient clinically important decrease in SF-36 Physical Functioning score (affecting activities such as walking, carrying groceries, climbing stairs) on Days 1 and 2 post-first vaccination. No clinically meaningful reductions in mean SF-36 Physical Functioning scale scores from pre- to post-RZV dose-1 were observed (mean +1.9 points, primary end point), and no overall quality-adjusted-life-year loss was recorded post-dose-1. Five participants reported lost workdays; caregiver workload was not increased. CONCLUSIONS: Overall, the physical functioning and quality of life of older adults were not affected by a first RZV dose. The observed reactogenicity was consistent with previous studies. Oxford University Press 2019-07 2018-09-25 /pmc/articles/PMC6625580/ /pubmed/30256905 http://dx.doi.org/10.1093/gerona/gly218 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of The Gerontological Society of America. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | The Journal of Gerontology: Translational Section Schmader, Kenneth E Levin, Myron J Grupping, Katrijn Matthews, Sean Butuk, David Chen, Michael Idrissi, Mohamed El Fissette, Laurence A Fogarty, Charles Hartley, Paul Klein, Nicola P Nevarez, Max Uusinarkaus, Kari Oostvogels, Lidia Curran, Desmond The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial |
title | The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial |
title_full | The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial |
title_fullStr | The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial |
title_full_unstemmed | The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial |
title_short | The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial |
title_sort | impact of reactogenicity after the first dose of recombinant zoster vaccine on the physical functioning and quality of life of older adults: an open-label, phase iii trial |
topic | The Journal of Gerontology: Translational Section |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625580/ https://www.ncbi.nlm.nih.gov/pubmed/30256905 http://dx.doi.org/10.1093/gerona/gly218 |
work_keys_str_mv | AT schmaderkennethe theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT levinmyronj theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT gruppingkatrijn theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT matthewssean theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT butukdavid theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT chenmichael theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT idrissimohamedel theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT fissettelaurencea theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT fogartycharles theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT hartleypaul theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT kleinnicolap theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT nevarezmax theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT uusinarkauskari theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT oostvogelslidia theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT currandesmond theimpactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT schmaderkennethe impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT levinmyronj impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT gruppingkatrijn impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT matthewssean impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT butukdavid impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT chenmichael impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT idrissimohamedel impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT fissettelaurencea impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT fogartycharles impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT hartleypaul impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT kleinnicolap impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT nevarezmax impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT uusinarkauskari impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT oostvogelslidia impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial AT currandesmond impactofreactogenicityafterthefirstdoseofrecombinantzostervaccineonthephysicalfunctioningandqualityoflifeofolderadultsanopenlabelphaseiiitrial |